Press Releases

 
Press Releases
  Date Title and Summary View
Dec 17, 2014
REDWOOD CITY, Calif., Dec. 17, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition will take effect as part of the annual re-ranking of the NASDAQ Biotechnology Index upon market open on Monday, December 22, 2014. The NASDAQ...
Dec 16, 2014
REDWOOD CITY, Calif., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that Stephen D. Harrison, M.A., Ph.D., has joined the company as senior vice president and chief scientific officer. Dr. Harrison, a biochemist and molecular biologist, is highly published and has extensive experience leading product-driven research...
Dec 15, 2014
REDWOOD CITY, Calif., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Patiromer for Oral Suspension (Patiromer FOS) for the treatment of hyperkalemia, a serious condition defined as abnormally elevated levels of...
Dec 3, 2014
REDWOOD CITY, Calif., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John A. Orwin, president and chief executive officer, will present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014 at 9:45 a.m. ET. To access the live webcasts and subsequent archived re...
Nov 21, 2014
Treatment with Patiromer FOS Resulted in a Decrease in Elevated Serum Potassium Levels in CKD Patients on RAAS Inhibitors Normal Potassium Levels Maintained More Effectively in Patiromer FOS Treated Patients than with Placebo More Patiromer FOS Treated Patients Able to Continue on RAAS Inhibitor Therapy than with Placebo, a pre...
Nov 20, 2014
REDWOOD CITY, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on November 17, 2014, the compensation committee of the company's board of directors granted new employee Scott Garland, the company's senior vice president and chief commercial officer, an option to purchase 100,00...
Nov 17, 2014
REDWOOD CITY, Calif., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data from clinical trials of the company's lead product candidate, Patiromer for Oral Suspension (Patiromer FOS), were presented at the American Society of Nephrology (ASN) Annual Meeting held last week in Philadelp...
Nov 12, 2014
REDWOOD CITY, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John A. Orwin, president and chief executive officer, will present at the Stifel Healthcare Conference on November, 19, 2014 at 8:00 a.m. ET. To access the live webcasts and subsequent archived recordings of...
Nov 10, 2014
REDWOOD CITY, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2014. Net loss for the third quarter 2014 was $19.4 million, or $0.57 per share, compared to $25.6 million, or $79.91 per share, for the comparable period in 201...
Nov 6, 2014
REDWOOD CITY, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced the launch of a new website entitled "Hyperkalemia Clinical Insights" (www.hyperkalemiainsights.com), which was developed by the company as an educational resource for healthcare professionals. Hyperkalemia is a serious condition defined as abnormall...
Page:
1
... NextLast
= add release to Briefcase